PubMed ID:
20512062
Public Release Type:
Journal
Publication Year: 2010
Affiliation: Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Colorado Denver School of Medicine and the Children's Hospital, Aurora, CO 80045, USA. narkewicz.michael@tchden.org
DOI:
https://doi.org/10.1097/MPG.0b013e3181b99cf0
Authors:
Hoofnagle JH,
Balistreri W,
Barton BA,
Billote GB,
Brown KM,
Chen K,
Doo E,
Drack A,
Duggan C,
Fauchere S,
Ferayorni L,
Garrett B,
Gonzalez-Peralta RP,
Goodman ZD,
Haber B,
Hawkins A,
Hodik M,
Jonas M,
Klipsch A,
Lieb W,
Lobritto S,
Margolis T,
McCarthy M,
Mocilnikar C,
Mohan P,
Molleston JP,
Murray KF,
Narkewicz MR,
Newman-Georges JO,
PEDS-C Study Group,
Repka MX,
Robuck PR,
Rosenthal P,
Roy A,
Schwarz KB,
Senz H,
Torrance R,
Young ML
Studies:
Pegylated Interferon +/- Ribavirin for Children with HCV
Interferon treatment for chronic viral hepatitis C (HCV) has been associated with the development of retinopathy in 19% to 29% of adults. Our purpose is to describe the ophthalmologic complications of pegylated interferon-alpha2a with either placebo or ribavirin in children with chronic HCV (the PEDS-C trial).